Oseltamivir: Difference between revisions
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Oseltamivir''' [[International Nonproprietary Name|INN]] {{IPAc-en|ɒ|s|əl|ˈ|t|æ|m|ɨ|v|ɪər}}, marketed under the [[trade name]] '''Tamiflu''', is an [[antiviral drug|antiviral]] licensed to prevent or slow the spread of [[influenza A virus|influenza A]] and [[Influenzavirus B|influenza B]] (flu) virus between cells in the body by stopping the virus from [[Viral neuraminidase|chemically cutting ties]] with its host cell.<ref name="pmid19665930">{{cite journal |author=Burch J |title=Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis |journal=Lancet Infect Dis |volume=9 |issue=9 |pages=537–45 |year=2009 |month=September |pmid=19665930 |doi=10.1016/S1473-3099(09)70199-9 |author-separator=, |author2=Corbett M |author3=Stock C |display-authors=3 |last4=Nicholson |first4=Karl |last5=Elliot |first5=Alex J |last6=Duffy |first6=Steven |last7=Westwood |first7=Marie |last8=Palmer |first8=Stephen |last9=Stewart |first9=Lesley }}</ref> The drug is taken orally in capsules or as a suspension. Oseltamivir is a [[prodrug]], a (relatively) inactive chemical, which is converted into its active form by metabolic process after it is taken into the body. It was the first orally active [[neuraminidase inhibitor]] commercially developed.{{Citation needed|date=February 2010}} It was developed by C.U. Kim, W. Lew, and X. Chen of US-based [[Gilead Sciences]],<ref>{{cite journal| author = Lew W, Chen X, Kim CU| title = Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor| journal = Curr. Med. Chem.| volume = 7| issue = 6| pages = 663–72| year = 2000| month = June| pmid = 10702632| doi=10.2174/0929867003374886}}</ref> and is marketed by [[Genentech]].<ref> | |||
{{cite web| work = Drugs@FDA| title = Tamiflu Approval, Review, and Labeling Information| publisher = [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA)| url = http://web.archive.org/web/20110521030440/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=TAMIFLU| accessdate = 2012-11-08}}</ref> | |||
==Category== | ==Category== | ||
Revision as of 15:41, 8 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Oseltamivir INN /ɒsəlˈtæm[invalid input: 'ɨ']vɪər/, marketed under the trade name Tamiflu, is an antiviral licensed to prevent or slow the spread of influenza A and influenza B (flu) virus between cells in the body by stopping the virus from chemically cutting ties with its host cell.[1] The drug is taken orally in capsules or as a suspension. Oseltamivir is a prodrug, a (relatively) inactive chemical, which is converted into its active form by metabolic process after it is taken into the body. It was the first orally active neuraminidase inhibitor commercially developed.[citation needed] It was developed by C.U. Kim, W. Lew, and X. Chen of US-based Gilead Sciences,[2] and is marketed by Genentech.[3]
Category
Antiviral
US Brand Names
TAMIFLU®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Oseltamivir phosphate is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. Oseltamivir carboxylate is an inhibitor of influenza virus neuraminidase affecting release of viral particles.
References
- ↑ Burch J; Corbett M; Stock C; et al. (2009). "Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis". Lancet Infect Dis. 9 (9): 537–45. doi:10.1016/S1473-3099(09)70199-9. PMID 19665930. Unknown parameter
|month=ignored (help); Unknown parameter|author-separator=ignored (help) - ↑ Lew W, Chen X, Kim CU (2000). "Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor". Curr. Med. Chem. 7 (6): 663–72. doi:10.2174/0929867003374886. PMID 10702632. Unknown parameter
|month=ignored (help) - ↑ "Tamiflu Approval, Review, and Labeling Information". Drugs@FDA. U.S. Food and Drug Administration (FDA). Retrieved 2012-11-08.